Related references
Note: Only part of the references are listed.Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients
Thomas Powles et al.
EUROPEAN JOURNAL OF CANCER (2015)
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy
Roberto Iacovelli et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients
Samir Kapadia et al.
ACTA ONCOLOGICA (2013)
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review
Xin Zhang et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2012)
Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer
Nancy E. Kemeny et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
